Redirecting the immune system to restore neural connections in neurodegenerative disease
The immune system is responsible for driving pathological processes in many diseases of the nervous system; to this end, MindImmune is developing novel therapeutics that target the immune system in neurodegenerative diseases.
Our Flagship Program
for Alzheimer’s Disease
MindImmune has identified an innate immune cell that typically exists in the periphery but can be recruited into the brain where it drives neuro-inflammation that can destroy neural connections. We are developing MITI-101, a first-in-class therapeutic monoclonal antibody that prevents these cells from entering the brain, blocking the immune attack in the brain to ‘nip Alzheimer’s disease in the blood’.
MindImmune scientists bring over a century of collective experience and know-how in CNS drug discovery to developing breakthrough therapeutics for brain disease.
MindImmune is advancing a first-in-class monoclonal antibody designed to keep harmful immune cells out of the brain, stopping inflammatory damage.
